Promising combo tackles nerve pain in rare blood conditions
NCT ID NCT05065554
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 20 times
Summary
This study tests whether adding acalabrutinib to standard rituximab therapy is safe and effective for people with nerve damage (neuropathy) linked to two blood conditions: IgM MGUS or Waldenstrom macroglobulinemia. The 12 participants receive both drugs to see if the combination reduces harmful IgM antibodies and improves nerve symptoms. The goal is better disease control without a cure, as ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROPATHY;PERIPHERAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
Conditions
Explore the condition pages connected to this study.